CD274 and melanoma: A study evaluating PD-L1 mRNA expression in plasma derived EVs to monitor therapeutic response in melanoma and NSCLC has reported decreased PD-L1 levels among patients who achieved partial and complete response while increased expression of EV PD-L1 was observed among non-responders following treatment with ICI [288].